The efficacy, safety, and ideal treatment duration of EGFR-TKIs following adjuvant chemotherapy for patients with completely resected EGFR-mutated NSCLC were not known until 2014, when this study was initiated. Here, EGFR is linked to non-small cell lung carcinoma.